Marksans Pharma Limited (MARKSANS)
ISIN: INE750C01026 Industry: Drug Manufacturers—General Sector: Healthcare Website
46.6
-1.9(-3.92%)

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations in North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the analgesic, anti-inflammatory, benign prostatic hyperplasia, epilepsy, hyperparathyroidism, diabetic and antidiabetic, pain management, neurology, hormonal, antifungal, antiulcerative, cardiovascular and central nervous system, vitamin, cough and cold, dermatology, gastrointestinal, cephalosporin, injectable, antibacterial, hypertension, oncology, and antibiotics and anti-allergic therapeutic areas. It also provides contract research and manufacturing services, as well as distributes generic pharma products. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Pricing Updates

TODAY'S HIGH

49.45

TODAY'S LOW

46.3

52 WEEK HIGH

97.6

52 WEEK LOW

43.55

Major Holders

% of Shares Held by
All Insider

49.62%

% of Shares Held by
Institutions

2.80%

% of Float Held by
Institutions

5.55%

Number of Institutions
Holding Shares

12

Company Overview

MARKET CAP

1936.89 Cr.

ETERPRISE VALUE

1693.44 Cr.

NO. OF SHARES

40.93 Cr.

BOOK VALUE

26.278

DIV. YIELD

0.25%

DEBT

45.67 Cr.

GROSS PROFIT

774.50 Cr.

CASH

322.70 Cr.

REVENUE

1432.69 Cr.

REVENUE/SHARE

35.249

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2021Mar 2020Mar 2019Mar 2018
Investments0000
Change To Liabilities47.62 Cr.66.57 Cr.9.03 Cr.-84.25 Cr.
Total cashflows from Investing Activities-44.89 Cr.-59.58 Cr.-13.47 Cr.-38.80 Cr.
Net Borrowings-3.20 Cr.-70.30 Cr.-6.67 Cr.17.06 Cr.
Total Cash from Financing Activities-15.28 Cr.-113.55 Cr.-20.77 Cr.3.38 Cr.
Other Liabilities7.13 Cr.7.89 Cr.-16.01 Cr.5.39 Cr.
Total Assets0000
Net Income238.53 Cr.120.75 Cr.80.43 Cr.35.80 Cr.
Change in Cash118.55 Cr.60.18 Cr.-6.86 Cr.14.66 Cr.
Effect of Exchange Rate0000
Total Cash from Operating Activities178.74 Cr.233.32 Cr.27.39 Cr.50.09 Cr.
Depreciation30.76 Cr.21.57 Cr.19.35 Cr.16.89 Cr.
Other Cashflows from Investing Activities1 Cr.4.26 Lakhs-33.30 Lakhs12.59 Lakhs
Dividends Paid-4.09 Cr.-29.50 Cr.-4.44 Cr.-2.46 Cr.
Change to Inventory-162.47 Cr.51.40 Cr.-75.12 Cr.-28.03 Cr.
Change to Account Receivables-42.31 Cr.-66.75 Cr.30.86 Lakhs70.67 Cr.
Other Cashflows from Financing Activities-7.98 Cr.-8.74 Cr.-9.65 Cr.-10.22 Cr.
Change to Net Income58.86 Cr.31.29 Cr.8.90 Cr.31.61 Cr.
Capital Expenditures-46.42 Cr.-59.90 Cr.-13.14 Cr.-38.93 Cr.

Financials

ParticularsMar 2021Mar 2020Mar 2019Mar 2018
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax302.16 Cr.157.17 Cr.104.30 Cr.49.79 Cr.
Minority Interest18.85 Cr.13.11 Cr.10.21 Cr.9.54 Cr.
Net Income313.09 Cr.170.23 Cr.112.29 Cr.59.53 Cr.
Selling General Administrative209.63 Cr.178.54 Cr.165.88 Cr.153.39 Cr.
Gross Profit774.50 Cr.558.23 Cr.491.89 Cr.380.37 Cr.
Ebit313.09 Cr.170.23 Cr.112.29 Cr.59.53 Cr.
Operating Income313.09 Cr.170.23 Cr.112.29 Cr.59.53 Cr.
Other Operating Expenses220.41 Cr.187.28 Cr.193.87 Cr.148.53 Cr.
Interest Expense-3.81 Cr.-5.81 Cr.-6.62 Cr.-7.42 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense63.62 Cr.36.41 Cr.23.86 Cr.13.99 Cr.
Total Revenue1380.05 Cr.1134.35 Cr.1000.06 Cr.912.69 Cr.
Total Operating Expenses1066.96 Cr.964.12 Cr.887.77 Cr.853.15 Cr.
Cost of Revenue605.55 Cr.576.12 Cr.508.16 Cr.532.32 Cr.
Total Other Income Expense Net-10.92 Cr.-13.06 Cr.-7.98 Cr.-9.73 Cr.
Discontinued OperationsNoneNoneNoneNone
Net Income from Continuous Ops.238.53 Cr.120.75 Cr.80.43 Cr.35.80 Cr.
Net Income Applicable to Common Shares238.53 Cr.120.75 Cr.80.43 Cr.35.80 Cr.

Balance Sheet

ParticularsMar 2021Mar 2020Mar 2019Mar 2018
Intangible Assets47.43 Cr.48.32 Cr.40.19 Cr.31.26 Cr.
Capital Surplus175.13 Cr.175.13 Cr.175.13 Cr.175.13 Cr.
Total Liabilities322.89 Cr.253.54 Cr.251 Cr.251.77 Cr.
Stock Holder Equity886.49 Cr.636.01 Cr.542.48 Cr.470.86 Cr.
Minority Interest18.85 Cr.13.11 Cr.10.21 Cr.9.54 Cr.
Other Liabilities95.13 Cr.88.50 Cr.18.57 Cr.31.26 Cr.
Total Assets1228.25 Cr.902.66 Cr.803.70 Cr.732.18 Cr.
Common Stock40.93 Cr.40.93 Cr.40.93 Cr.40.93 Cr.
Retained Earnings648.66 Cr.398.84 Cr.316.71 Cr.244.66 Cr.
Other Liabilities10.17 Cr.12.26 Cr.8.38 Cr.7.09 Cr.
Good Will19.58 Cr.24.37 Cr.31.44 Cr.61.74 Cr.
Treasury Stock21.76 Cr.21.10 Cr.9.70 Cr.10.13 Cr.
Other Assets4.95 Cr.6.36 Cr.2.54 Cr.2.27 Cr.
Cash212.28 Cr.93.72 Cr.33.53 Cr.39.87 Cr.
Current Liabilities298.39 Cr.228.75 Cr.232.62 Cr.234.67 Cr.
Long Term Asset Charges79.85 Lakhs63.41 Lakhs1.24 Cr.1.45 Cr.
Short Long Term Debt04.58 Lakhs30.78 Lakhs54.88 Lakhs
Other Stockholder Equity21.76 Cr.21.10 Cr.9.70 Cr.10.13 Cr.
Property Plant Equipment254.02 Cr.230.01 Cr.198.08 Cr.186.36 Cr.
Total Cur. Assets902.25 Cr.593.58 Cr.531.44 Cr.450.53 Cr.
Long Term Investments0000
Net Tangible Assets819.47 Cr.563.31 Cr.470.83 Cr.377.85 Cr.
Short Term Investments0000
Net Receivables271.38 Cr.243.35 Cr.183.61 Cr.182.59 Cr.
Long Term Debt5 Cr.5 Cr.10 Cr.10 Cr.
Inventory404.31 Cr.241.84 Cr.293.24 Cr.218.12 Cr.
Accounts Payable168.66 Cr.110.32 Cr.106.06 Cr.77.82 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account